These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

76 related articles for article (PubMed ID: 28689890)

  • 1. The dose-dense principle in chemotherapy.
    López ÁG; Iarosz KC; Batista AM; Seoane JM; Viana RL; Sanjuán MAF
    J Theor Biol; 2017 Oct; 430():169-176. PubMed ID: 28689890
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of Tailored Dose-Dense Chemotherapy vs Standard 3-Weekly Adjuvant Chemotherapy on Recurrence-Free Survival Among Women With High-Risk Early Breast Cancer: A Randomized Clinical Trial.
    Foukakis T; von Minckwitz G; Bengtsson NO; Brandberg Y; Wallberg B; Fornander T; Mlineritsch B; Schmatloch S; Singer CF; Steger G; Egle D; Karlsson E; Carlsson L; Loibl S; Untch M; Hellström M; Johansson H; Anderson H; Malmström P; Gnant M; Greil R; Möbus V; Bergh J;
    JAMA; 2016 Nov; 316(18):1888-1896. PubMed ID: 27825007
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New approaches to adjuvant chemotherapy for breast cancer.
    Hudis C
    Pharmacotherapy; 1996; 16(3 Pt 2):88S-93S. PubMed ID: 8726587
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Concepts and clinical trials of dose-dense chemotherapy for breast cancer .
    Orzano JA; Swain SM
    Clin Breast Cancer; 2005 Dec; 6(5):402-11. PubMed ID: 16381623
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Dose intensity in cancer chemotherapy: definition, average relative dose intensity and effective dose intensity].
    Alberto P
    Bull Cancer; 1995; 82 Suppl 1():3s-8s. PubMed ID: 7626852
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Norton-Simon hypothesis: designing more effective and less toxic chemotherapeutic regimens.
    Simon R; Norton L
    Nat Clin Pract Oncol; 2006 Aug; 3(8):406-7. PubMed ID: 16894366
    [No Abstract]   [Full Text] [Related]  

  • 7. Revisiting Dosing Regimen Using Pharmacokinetic/Pharmacodynamic Mathematical Modeling: Densification and Intensification of Combination Cancer Therapy.
    Meille C; Barbolosi D; Ciccolini J; Freyer G; Iliadis A
    Clin Pharmacokinet; 2016 Aug; 55(8):1015-25. PubMed ID: 26946136
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sequence effect of docetaxel and carboplatin on toxicity, tumor response and pharmacokinetics in non-small-cell lung cancer patients: a phase I study of two sequences.
    Ando M; Saka H; Ando Y; Minami H; Kuzuya T; Yamamoto M; Watanabe A; Sakai S; Shimokata K; Hasegawa Y
    Cancer Chemother Pharmacol; 2005 Jun; 55(6):552-8. PubMed ID: 15856233
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized phase III trial of dose-dense chemotherapy supported by whole-blood hematopoietic progenitors in better-prognosis small-cell lung cancer.
    Lorigan P; Woll PJ; O'Brien ME; Ashcroft LF; Sampson MR; Thatcher N
    J Natl Cancer Inst; 2005 May; 97(9):666-74. PubMed ID: 15870437
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of rapidly cycled tandem high-dose chemotherapy plus peripheral-blood stem-cell support versus dose-dense conventional chemotherapy for adjuvant treatment of high-risk breast cancer: results of a multicentre phase III trial.
    Nitz UA; Mohrmann S; Fischer J; Lindemann W; Berdel WE; Jackisch C; Werner C; Ziske C; Kirchner H; Metzner B; Souchon R; Ruffert U; Schütt G; Pollmanns A; Schmoll HJ; Middecke C; Baltzer J; Schrader I; Wiebringhaus H; Ko Y; Rösel S; Schwenzer T; Wernet P; Hinke A; Bender HG; Frick M;
    Lancet; 2005 Dec; 366(9501):1935-44. PubMed ID: 16325695
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Achieving full-dose, on-schedule administration of ACE chemotherapy every 14 days for the treatment of patients with extensive small-cell lung cancer.
    Pirker R; Ulsperger E; Messner J; Aigner K; Forstner B; Bacon P; Easton V; Skacel T
    Lung; 2006; 184(5):279-85. PubMed ID: 17235728
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dose-dense chemotherapy for primary breast cancer.
    Kümmel S; Rezai M; Kimmig R; Schmid P
    Curr Opin Obstet Gynecol; 2007 Feb; 19(1):75-81. PubMed ID: 17218856
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dose-dense chemotherapy for breast cancer: what does the future hold?
    Morris PG; McArthur HL; Hudis C; Norton L
    Future Oncol; 2010 Jun; 6(6):951-65. PubMed ID: 20528233
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Internet-based system for anti-tumor chemotherapy evaluation.
    Klimes D; Kubasek M; Smid R; Dusek L
    Comput Methods Programs Biomed; 2009 Mar; 93(3):292-6. PubMed ID: 19084288
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The mathematical modelling of adjuvant chemotherapy scheduling: incorporating the effects of protocol rest phases and pharmacokinetics.
    Gaffney EA
    Bull Math Biol; 2005 May; 67(3):563-611. PubMed ID: 15820743
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase II study of modified dose-dense paclitaxel and every 4-week carboplatin for the treatment of advanced-stage primary epithelial ovarian, fallopian tube, or peritoneal carcinoma.
    Abaid LN; Micha JP; Rettenmaier MA; Brown JV; Mendivil AA; Lopez KL; Goldstein BH
    Cancer Chemother Pharmacol; 2013 Jul; 72(1):101-7. PubMed ID: 23660691
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epirubicin and paclitaxel with G-CSF support in first line metastatic breast cancer: a randomized phase II study of dose-dense and dose-escalated chemotherapy.
    Lalisang RI; Erdkamp FL; Rodenburg CJ; Knibbeler-van Rossum CT; Nortier JW; van Bochove A; Slee PH; Voest EE; Wils JA; Wals J; Loosveld OJ; Smals AE; Blijham GH; Tjan-Heijnen VC; Schouten HC
    Breast Cancer Res Treat; 2011 Jul; 128(2):437-45. PubMed ID: 21584666
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Selecting combinations of chemotherapeutic drugs to maximize dose intensity.
    Simon R; Korn EL
    J Biopharm Stat; 1991; 1(2):247-59. PubMed ID: 1844700
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of high-dose cyclophosphamide, cisplatin, and carmustine pharmacokinetics with survival, toxicity, and dosing weight in patients with primary breast cancer.
    Petros WP; Broadwater G; Berry D; Jones RB; Vredenburgh JJ; Gilbert CJ; Gibbs JP; Colvin OM; Peters WP
    Clin Cancer Res; 2002 Mar; 8(3):698-705. PubMed ID: 11895898
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The application of mathematical modelling to aspects of adjuvant chemotherapy scheduling.
    Gaffney EA
    J Math Biol; 2004 Apr; 48(4):375-422. PubMed ID: 15052504
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.